Shreyaskumar R. Patel

Shreyaskumar Patel practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Shreyaskumar Patel's NPI, 1588750095, was assigned on October 4, 2006. Shreyaskumar Patel graduated from Baroda Medical College in 1983. Shreyaskumar Patel's Texas license number on file is H8791.

Shreyaskumar Patel's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Shreyaskumar Patel's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Shreyaskumar Patel practices. Vendor and product names are available with a free account.

Medical oncology is Shreyaskumar Patel's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Shreyaskumar Patel is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Shreyaskumar Patel's licenses on file in 5 states: Texas, Florida, Michigan, Oklahoma and Minnesota.

Dmand AI lists chronic anemia, chronic hypertension, congestive heart failure, sepsis and tobacco use among the conditions Shreyaskumar Patel treats.

CMS data shows 181 Medicare services from Shreyaskumar Patel across 2 procedure codes in 2024, all of them office visits, for 127 Medicare patients. Medicare paid $19,235 for them.

CMS counts 127 Medicare patients who saw Shreyaskumar Patel in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Shreyaskumar Patel's median patient age at 69, with 52% women.

In 2024, Shreyaskumar Patel wrote 199 Medicare Part D claims for 33 patients. 80% of them were for generic drugs. CMS names the drug for 101 of them, across 6 drugs with 11 or more claims each, at $758,290 in total drug cost. In 2023, CMS named 73 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Shreyaskumar Patel for performance year 2024, reported as part of a group. Shreyaskumar Patel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Shreyaskumar Patel as offering telehealth.

Dmand AI links 135 papers to Shreyaskumar Patel, published from 2005 to 2024. 2017 was the busiest year, with 10. The most frequent topics are Sarcoma, Antineoplastic Combined Chemotherapy Protocols and Antineoplastic Agents. Shreyaskumar Patel has published most often in Cancer. Shreyaskumar Patel's most frequent co-authors are Robert S. Benjamin, MD, Wei - Lien Wang, MD and Vinod Ravi, MD.

Dmand AI links Shreyaskumar Patel to 1 clinical trial. Conditions studied include Leiomyosarcoma and Neoplasms, Muscle Tissue. Open Payments lists research payments to Shreyaskumar Patel that name 1 trial.

CMS Open Payments shows 222 general payments to Shreyaskumar Patel from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. Daiichi Sankyo Inc. paid the most, $62,350. It also lists 11 research payments totaling $1,294 in 2023, naming 1 clinical trial.

Shreyaskumar Patel graduated from Baroda Medical College in 1983.

Shreyaskumar Patel is in network with 4 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 3. Check the plan with the practice before a visit.